Pharmacodynamic endpoints in primary breast cancer

Annals of Oncology

Volumn 18, Issue SUPPL. 9, 2007, Pages

  Di Cosimo, S ^a   Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; KI 67 ANTIGEN; LAPATINIB; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EVIDENCE BASED PRACTICE; HUMAN; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; BREAST TUMOR; FEMALE; METABOLISM; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 36049011272     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm288     Document Type: Conference Paper

References (16)

1. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000; 287: 1969-1973.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med 2001; 344: 783-792.
4. Gelmon KA, Eisenhauer EA, Harris AL et al. Anticancer agents targeting signalling molecules and the cancer cell environment. J Natl Cancer Inst 1999; 91: 1281-1287.
5. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2: 566-580.
6. Park JW, Kerbel RS, Kelloff GJ et al. Rationale for biomarkers and surrogate end points in mechanism driven oncology drug development. Clin Cancer Res 2004; 10: 3885-3896.
7. Baselga J. Skin as a surrogate tissue for pharmacodynamic end points: Is it deep enough? Clin Cancer Res 2003; 9: 2389-2390.
8. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110-124.
9. Tabernero J, Rojo F, Burris H et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2005; 23: No. 16S Part I of II; 193s (abstract 3007).
10. Collins JM. Functional imaging in phase I studies: Decorations or decision making? J Clin Oncol 2003; 21: 2807-2809.
11. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
12. Mohsin SK, Weiss HL, Gutierrez MC et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005; 23: 2460-2468.
13. Baselga J, Albanell J, Ruiz A et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005; 23: 5323-5333.
14. Moss B, Goss PE. Lapatinib: Current status and future directions in breast cancer. Oncologist 2006; 11: 1047-1057.
15. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23: 5108-5116.
16. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.